We are live on
!
Find out more
AA
AlphaCentric Advisors Portfolio holdings
AUM
$100M
This Fund
S&P 500
This Quarter
Est. Return
-0.63%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$145M
AUM Growth
+$43.7M
(+43%)
Cap. Flow
+$49.2M
Cap. Flow
% of AUM
33.95%
Top 10 Holdings %
Top 10 Hldgs %
24.02%
Holding
223
New
58
Increased
36
Reduced
83
Closed
14
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares 1-3 Year Treasury Bond ETF
SHY
|
+$6.28M |
| 2 |
Centene
CNC
|
+$3.55M |
| 3 |
Harmony Biosciences
HRMY
|
+$3.07M |
| 4 |
BioCryst Pharmaceuticals
BCRX
|
+$2.84M |
| 5 |
Invesco QQQ Trust
QQQ
|
+$2.58M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Aurinia Pharmaceuticals
AUPH
|
+$2.42M |
| 2 |
PennyMac Financial
PFSI
|
+$1.76M |
| 3 |
AirSculpt Technologies
AIRS
|
+$1.33M |
| 4 |
Starwood Property Trust
STWD
|
+$1.19M |
| 5 |
Ametek
AME
|
+$1.05M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 56.03% |
| 2 | Real Estate | 10.47% |
| 3 | Financials | 4.37% |
| 4 | Energy | 4.28% |
| 5 | Technology | 3.06% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
iShares 1-3 Year Treasury Bond ETF
SHY
$25.7B
| $6.33M | 4.37% |
+76,992
| New | +$6.28M |
|
2
Rithm Capital
RITM
$5.2B
| $3.93M | 2.71% |
491,699
| – | – |
|
|
LKFT
3
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.97B
| $3.55M | 2.45% |
92,000
+49,500
| +116% | +$2.03M |
|
|
4
BioCryst Pharmaceuticals
BCRX
$2.36B
| $3.5M | 2.41% |
419,500
+294,500
| +236% | +$2.84M |
|
|
5
Centene
CNC
$32.8B
| $3.16M | 2.18% |
+50,000
| New | +$3.55M |
|
|
TSVT
6
DELISTED
2seventy bio
TSVT
| $3.09M | 2.13% |
302,500
+122,500
| +68% | +$1.4M |
|
7
GSK
GSK
$104B
| $2.85M | 1.96% |
80,000
+19,000
| +31% | +$665K |
|
|
8
Invesco QQQ Trust
QQQ
$466B
| $2.81M | 1.94% |
+8,749
| New | +$2.58M |
|
9
Invesco NASDAQ 100 ETF
QQQM
$96.3B
| $2.81M | 1.94% |
+21,262
| New | +$2.58M |
|
|
HZNP
10
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $2.78M | 1.92% |
25,500
| – | – |
|
|
EFC
11
Ellington Financial
EFC
$1.7B
| $2.44M | 1.69% |
200,171
+35,017
| +21% | +$451K |
|
12
Coherus Oncology
CHRS
$216M
| $2.42M | 1.67% |
354,500
+167,000
| +89% | +$1.3M |
|
|
COOP
13
DELISTED
Mr. Cooper
COOP
| $2.33M | 1.61% |
56,790
| – | – |
|
|
14
Harmony Biosciences
HRMY
$1.96B
| $2.2M | 1.52% |
+67,500
| New | +$3.07M |
|
15
Arcutis Biotherapeutics
ARQT
$3.56B
| $2.09M | 1.44% |
190,000
+111,500
| +142% | +$1.61M |
|
16
Innoviva
INVA
$1.6B
| $2.07M | 1.43% |
184,000
+109,000
| +145% | +$1.32M |
|
17
Elanco Animal Health
ELAN
$12.9B
| $2.02M | 1.39% |
215,000
+112,500
| +110% | +$1.33M |
|
18
Lantheus
LNTH
$7B
| $1.9M | 1.31% |
23,000
+6,000
| +35% | +$387K |
|
|
MFA
19
MFA Financial
MFA
$960M
| $1.72M | 1.19% |
173,425
+15,195
| +10% | +$161K |
|
|
ADAM
20
Adamas Trust
ADAM
$807M
| $1.71M | 1.18% |
172,079
+23,146
| +16% | +$251K |
|
21
Bio-Rad Laboratories Class A
BIO
$8.15B
| $1.63M | 1.12% |
3,400
| – | – |
|
22
Neurocrine Biosciences
NBIX
$17.2B
| $1.57M | 1.08% |
+15,500
| New | +$1.61M |
|
23
ADC Therapeutics
ADCT
$172M
| $1.48M | 1.02% |
760,000
+462,500
| +155% | +$1.71M |
|
24
Pacira BioSciences
PCRX
$1.01B
| $1.47M | 1.01% |
36,000
+17,000
| +89% | +$676K |
|
25
AdaptHealth
AHCO
$1.49B
| $1.45M | 1% |
+116,500
| New | +$2.14M |
|
Similar funds
WCM
FCM
BIA
AGAM
E
HCM
AC
OIS
AlphaCentric Advisors's Q1 2023 Portfolio in Review
As of Q1 2023, AlphaCentric Advisors held 223 positions worth $145M, up 43% from $101M the previous quarter. Its ten largest holdings account for 24% of the portfolio.
AlphaCentric Advisors deployed $49.2M of net new capital in Q1 2023, opening 58 new positions and adding to 36 existing holdings. Its largest new stake was iShares 1-3 Year Treasury Bond ETF: 76,992 shares worth $6.33M.
By sector, the portfolio is most concentrated in Healthcare at 56% of assets, down from 57% a quarter earlier, followed by Real Estate and Financials.
On the sell side, the largest reduction was Aurinia Pharmaceuticals, an estimated $2.42M trimmed.
- AlphaCentric Advisors's largest Q1 2023 buy was iShares 1-3 Year Treasury Bond ETF: 76,992 shares worth $6.33M.
- AlphaCentric Advisors added most to BioCryst Pharmaceuticals in Q1 2023, an estimated $2.84M increase.
- AlphaCentric Advisors's biggest Q1 2023 reduction was Aurinia Pharmaceuticals, cutting an estimated $2.42M.
- AlphaCentric Advisors fully exited PennyMac Financial in Q1 2023, selling an estimated $1.76M.
- AlphaCentric Advisors's ten largest holdings make up 24% of its $145M portfolio in Q1 2023.
- AlphaCentric Advisors opened 58 new positions and closed 14 in Q1 2023.
- AlphaCentric Advisors's portfolio value rose 43% quarter-over-quarter to $145M.
Based on AlphaCentric Advisors's 13F filing for Q1 2023, filed 12 May 2023.